Concepedia

Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia

Patrice Chevallier, Virginie Roland, Beatrice Mahé, Nadine Juge‐Morineau, Viviane Dubruille, Thierry Guillaume, Stéphane Vigouroux, Philippe Moreau, Nöel Milpied, Richard Garand,

Leukemia Research · 2005 · 37 citations · 19 references

DOI

Concepts

References

19

Acute Myeloid Leukemia

Bob Löwenberg, James R. Downing, Alan K. Burnett · New England Journal of Medicine · 1999 · 1.2K citations

, , +14

Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

Eric L. Sievers, Richard A. Larson, Edward A. Stadtmauer et al. · Journal of Clinical Oncology · 2001 · 893 citations

, , +17

Expression of normal myeloid-associated antigens by acute leukemia cells

PA Dinndorf, RG Andrews, D Benjamin et al. · Blood · 1986 · 226 citations

, , +12

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)

M. A. Boogaerts, Elihu H. Estey, Chatchada Karanes et al. · Leukemia · 2002 · 223 citations

, , +17

Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

Michael Linenberger, Tom C. Hong, David Flowers et al. · Blood · 2001 · 199 citations · Full text

, , +13